Education
About Us
Working with TipRanks
Follow Us
Idexx Laboratories (IDXX)
NASDAQ:IDXX
IDXX Analyst Ratings
Moderate Buy
6 Buy
3 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
IDXX Stock 12 Month Forecast
Average Price Target
$725.22
▲(9.23% Upside)
| Highest Price Target$785.00 | Average Price Target$725.22 | Lowest Price Target$640.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
William Blair
―
Buy
―
Reiterated
08/14/25
Idexx Laboratories: A Strong Buy Amidst Veterinary Healthcare Market ResilienceWe continue to view the veterinary healthcare market as a relative safe haven investment area for investors, and we believe the industry is fairly recession resilient (i.e., largely inelastic demand, solid pricing power, and favorable demographic trends) and lacks many of the investment risks present in the human healthcare space. Given the above, we have conviction in the company’s management team, long- term organic growth trajectory, and business franchise overall; thus, we view Idexx as a core long-term holding and reiterate our Outperform rating on the stock.
Piper Sandler
$510→$700
Hold
5.43%
Upside
Reiterated
08/11/25
TR | OpenAI - 4o
$775
Buy
16.73%
Upside
Reiterated
08/11/25
Leerink Partners
$600→$745
Buy
12.21%
Upside
Reiterated
08/06/25
Morgan Stanley
$628→$722
Sell
8.75%
Upside
Downgraded
08/05/25
Idexx Laboratories: Strong Financial Performance and Strategic Outlook Justify Buy RatingWe await further insight on the call (at 8:30AM ET) on what is embedded in guidance, competitive positioning, corporate relationships, the outlook for vet visits, utilization trends, and color on the consumer / macro backdrop. Moreover, we look for more color on its ramping inVue Dx launch (and expansion into FNA - expected approval in 2025), Cancer Dx (launched in March 2025), and its other yet-to-be-announced VetLab Dx platform that will bring new testing capabilities (we estimate this may be fecal testing). Note, it previously pointed to 4,500 placements by year end (vs. 2,690 placements YTD), and we await clarity on the call on the ramp. Net/net, our conviction in IDXX's highly defensible leadership position and innovation drivers is intact in the attractive dog’nostics market longer term. Next key catalyst will also be August 13-14.
Jefferies
$625→$785
Buy
18.24%
Upside
Reiterated
08/05/25
BTIG
$545→$785
Buy
18.24%
Upside
Reiterated
08/05/25
Stifel Nicolaus
$540→$640
Hold
-3.60%
Downside
Reiterated
08/04/25
Bank of America Securities
$550→$700
Hold
5.43%
Upside
Reiterated
08/04/25
J.P. Morgan
$550→$675
Buy
1.67%
Upside
Reiterated
08/04/25
Barclays
$520
Buy
-21.68%
Downside
Reiterated
02/04/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
William Blair
―
Buy
―
Reiterated
08/14/25
Idexx Laboratories: A Strong Buy Amidst Veterinary Healthcare Market ResilienceWe continue to view the veterinary healthcare market as a relative safe haven investment area for investors, and we believe the industry is fairly recession resilient (i.e., largely inelastic demand, solid pricing power, and favorable demographic trends) and lacks many of the investment risks present in the human healthcare space. Given the above, we have conviction in the company’s management team, long- term organic growth trajectory, and business franchise overall; thus, we view Idexx as a core long-term holding and reiterate our Outperform rating on the stock.
Piper Sandler
$510→$700
Hold
5.43%
Upside
Reiterated
08/11/25
TR | OpenAI - 4o
$775
Buy
16.73%
Upside
Reiterated
08/11/25
Leerink Partners
$600→$745
Buy
12.21%
Upside
Reiterated
08/06/25
Morgan Stanley
$628→$722
Sell
8.75%
Upside
Downgraded
08/05/25
Idexx Laboratories: Strong Financial Performance and Strategic Outlook Justify Buy RatingWe await further insight on the call (at 8:30AM ET) on what is embedded in guidance, competitive positioning, corporate relationships, the outlook for vet visits, utilization trends, and color on the consumer / macro backdrop. Moreover, we look for more color on its ramping inVue Dx launch (and expansion into FNA - expected approval in 2025), Cancer Dx (launched in March 2025), and its other yet-to-be-announced VetLab Dx platform that will bring new testing capabilities (we estimate this may be fecal testing). Note, it previously pointed to 4,500 placements by year end (vs. 2,690 placements YTD), and we await clarity on the call on the ramp. Net/net, our conviction in IDXX's highly defensible leadership position and innovation drivers is intact in the attractive dog’nostics market longer term. Next key catalyst will also be August 13-14.
Jefferies
$625→$785
Buy
18.24%
Upside
Reiterated
08/05/25
BTIG
$545→$785
Buy
18.24%
Upside
Reiterated
08/05/25
Stifel Nicolaus
$540→$640
Hold
-3.60%
Downside
Reiterated
08/04/25
Bank of America Securities
$550→$700
Hold
5.43%
Upside
Reiterated
08/04/25
J.P. Morgan
$550→$675
Buy
1.67%
Upside
Reiterated
08/04/25
Barclays
$520
Buy
-21.68%
Downside
Reiterated
02/04/25
Best Analysts Covering Idexx Laboratories
1 Month
xxx
Success Rate
8/16 ratings generated profit
Average Return
-0.11%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -0.11% per trade.
3 Months
xxx
Success Rate
14/26 ratings generated profit
Average Return
+2.12%
downgraded a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +2.12% per trade.
1 Year
Success Rate
19/26 ratings generated profit
Average Return
+24.56%
downgraded a sell rating 11 days ago
Copying Erin Wright's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +24.56% per trade.
2 Years
xxx
Success Rate
21/26 ratings generated profit
Average Return
+36.20%
downgraded a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.77% of your transactions generating a profit, with an average return of +36.20% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
IDXX Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
0
Buy
8
8
9
14
18
Hold
9
8
6
5
5
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
17
16
15
19
24
Each month's total comprises the sum of three months' worth of ratings.
IDXX Financial Forecast
IDXX Stock Forecast FAQ
What is IDXX’s average 12-month price target, according to analysts?
Based on analyst ratings, Idexx Laboratories’s 12-month average price target is 725.22.
What is IDXX’s upside potential, based on the analysts’ average price target?
Idexx Laboratories has 9.23% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IDXX a Buy, Sell or Hold?
Idexx Laboratories has a consensus rating of Moderate Buy which is based on 6 buy ratings, 3 hold ratings and 1 sell ratings.
What is Idexx Laboratories’s price target?
The average price target for Idexx Laboratories is 725.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $785.00 ,the lowest forecast is $640.00. The average price target represents 9.23% Increase from the current price of $663.92.
The highest analyst price target is $785.00 ,the lowest forecast is $640.00. The average price target represents 9.23% Increase from the current price of $663.92.
What do analysts say about Idexx Laboratories?
Idexx Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of IDXX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.